Biochemical markers of cardiac diseases

Jugoslovenska Medicinska Biohemija

Volumn 23, Issue 3, 2004, Pages 201-211

  Panteghini, Mauro ^a  

^a SPEDALI CIVILI   (Italy)

Author keywords

Biological markers; Diagnosis; Myocardial infarction; Troponin

Indexed keywords

ALBUMIN; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CD40 LIGAND; CHOLESTEROL; CREATINE; CREATINE KINASE MB; FATTY ACID; GLYCOGEN PHOSPHORYLASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NATRIURETIC FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TROPONIN;

ACUTE DISEASE; ACUTE HEART INFARCTION; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL LABORATORY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY DIAGNOSIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; RELIABILITY;

EID: 4644253523     PISSN: 03543447     EISSN: None     Source Type: Journal    
DOI: 10.2298/JMH0403201P     Document Type: Conference Paper

References (113)

1. Lefkowitz RJ, Willerson JT. Prospects for cardiovascular research. JAMA 2001; 285: 581-7.
2. Beller GA. Coronary heart disease in the first 30 years of the 21st century: challenges and opportunities. Circulation 2001; 103: 2428-35.
3. Diop D, Aghababian RV. Definition, classification, and pathophysiology of acute coronary ischemic syndromes. Emerg Med Clin North Am 2001; 19: 259-67.
4. Kahn SE. The challenge of evaluating the patient with chest pain. Arch Pathol Lab Med 2000; 124: 1418-9.
5. Lee TH, Goldman L. Evaluation of the patient with acute chest pain. N Engl J Med 2000; 342: 1187-95.
6. Davis RC, Hobbs FDR, Up GYH. ABC of heart failure. History and epidemiology. Br Med J 2000; 320: 39-42.
7. Panteghini M. Acute coronary syndrome. Biochemical strategies in the troponin era. Chest 2002; 122: 1428-35.
8. Clerico A. The increasing impact of laboratory medicine on clinical cardiology. Clin Chem Lab Med 2003; 41: 871-83.
9. Collinson PO. Early diagnosis of myocardial infarction: why measure cardiac enzymes? J Clin Pathol 1998; 51: 2-4.
10. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the management of patients with unstable angina). J Am Coll Cardiol 2000; 36: 970-1062.
11. Bertrand ME, Simoons ML, Fox KAA et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40.
12. Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet 2001; 358: 1533-8.
13. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.
14. Alpert J, Thygesen K for the Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined-A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 2000; 21: 1502-13.
15. Nomenclature and Criteria for Diagnosis of Ischemic Heart Disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Circulation 1979; 59: 607-8.
16. Panteghini M, Apple FS, Christenson RH et al. Use of biochemical markers in acute coronary syndromes. Clin Chem Lab Med 1999; 37: 687-93.
17. Jaffe AS, Ravkilde J, Roberts R et al. It's time for a change to a troponin standard. Circulation 2000; 102: 1216-20.
18. Hamm CW. Acute coronary syndromes. The diagnostic role of troponins. Thromb Res 2001; 103: S63-9.
19. Panteghini M, Pagani F, Bonetti G. The sensitivity of cardiac markers: an evidence-based approach. Clin Chem Lab Med 1999; 37: 1097-106.
20. Panteghini M, Cuccia C, Pagani F et al. Coronary angiographic findings in patients with clinical unstable angina according to cardiac troponin 1 and T concentrations in serum. Arch Pathol Lab Med 2002; 126: 448-51.
21. Gupta M, Lent RW, Kaplan EL et al. Serum cardiac troponin 1 in acute rheumatic fever. Am J Cardiol 2002; 89: 779-82.
22. Dispenzieri A, Kyle RA, Gertz MA et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787-9.
23. Sybrandy KC, Cramer MJM, Burgersdijk C. Diagnosing cardiac contusion: old wisdom and new insights. Heart 2003; 89: 458-89.
24. Dworschak M, Franz M, Khazen C et al. Mechanical trauma as the major cause of troponin T release after transvenous implantation of cardioverter/defibrillators. Cardiology 2001; 95: 212-4.
25. Kannankeril PJ, Pahl E, Wax DF. Usefulness of troponin 1 as a marker of myocardial injury after pediatric cardiac catheterization. Am J Cardiol 2002; 90: 1128-32.
26. Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin 1 release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517-22.
27. Sato Y, Yamada T, Taniguchi R et al. Persistently increased serum concentrations of cardiac troponin T in patient with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103: 369-74.
28. Horwich TB, Patel J, MacLellan WR et al. Cardiac troponin 1 is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108: 833-8.
29. Wright RS, Williams BA, Cramner H et al. Elevations of cardiac troponin 1 are associated with increased short-term mortality in noncardiac critically ill emergency department patients. Am J Cardiol 2002; 90: 634-6.
30. Ammann P, Maggiorini M, Bertel O et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol 2003; 41: 2004-9.
31. Apple FS, Murakami MM, Pearce LA et al. Predictive value of cardiac troponin 1 and T for subsequent death in end-stage renal disease. Circulation 2002; 106: 2941-5.
32. Gaze DC, Lawson GJ, Harris A et al. Evidence of myocyte necrosis in glycogen storage disease type II. Clin Chem 2003; 49 (suppl): A39.
33. Chance JJ, Segal JB, Wallerson G et al. Cardiac troponin T and C-reactive protein as markers of acute cardiac allograft rejection. Clin Chim Acta 2001; 312: 31-9.
34. Missov E, Mentzer W, Laprade M et al. Cardiac markers of injury in hemoglobinopathy patients with transfusion hemosiderosis. J Am Coll Cardiol 2001; 37: 470A.
35. Hamwi SM, Sharma AK, Weissman NJ et al. Troponin-1 elevation in patients with increased left ventricular mass. Am J Cardiol 2003; 92: 88-90.
36. Fleming SM, O'Gorman T, Finn J et al. Cardiac troponin 1 in pre-eclampsia and gestational hypertension. Br J Obstet Gynaecol 2000; 107: 1417-20.
37. Arlati S, Brenna S, Prencipe L et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intensive Care Med 2000; 26: 31-7.
38. Mutch WJ, Kulkarmi UV, Croal BL et al. Cardiac marker levels in hypothyroidism. Clin Chem 2001; 47 (suppl): A199.
39. Lauer B, Niederau C, Kuhl U et al. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 1997; 30: 1354-9.
40. Brandt RR, Filzmaier K, Hanrath P. Circulating cardiac troponin 1 in acute pericarditis. Am J Cardiol 2001; 87: 1326-8.
41. Lopez-Jimenez F, Goldman L, Sacks DB et al. Prognostic value of cardiac troponin T after noncardiac surgery: 6-month follow-up data. J Am Coll Cardiol 1997; 29: 1241-5.
42. Giannitsis E, Muller-Bardorff M, Kurowski V et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000; 102: 211-7.
43. Spies C, Haude V, Fitzner R et al. Serum cardiac troponin T as a prognostic marker in early sepsis. Chest 1998; 113: 1055-63.
44. Collinson PO, Stubbs PJ. Are troponins confusing? Heart 2003; 89: 1285-7.
45. Galvani M, Panteghini M, Ottani F et al. The new definition of myocardial infarction: analysis of the ESC/ACC consensus document and reflections on its applicability to the Italian Health System, Ital Heart J 2002; 3: 543- 57.
46. Panteghini M. Recommendations on use of biochemical markers in acute coronary syndrome: IFCC proposals. eJIFCC 14: http://www.ifcc.org/ejifcc/ vol14no2/1402062003014n.htm
47. Jaffe A. Caveat emptor. Am J Med 2003; 115: 241-4.
48. Morrow DA, Cannon CP, Rifai N et al. Ability of minor elevations of troponins 1 and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001; 286: 2405-12.
49. Venge P, Lagerqvist B, Diderholm E et al. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease. Am J Cardiol 2002; 89: 1035-41.
50. James S, Armstrong P, Califf R et al. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med 2003; 115: 178-84.
51. Apple FS, Wu AHB. Myocardial infarction redefined: role of cardiac troponin testing. Clin Chem 2001; 47: 377-9.
52. Apple FS, Quist HE, Doyle PJ et al. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003; 49: 1331-6.
53. Panteghini M, Pagani F, Yeo KTJ et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004; 50: 327-32.
54. Apple FS, Wu AH, Jaffe AS. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J 2002; 144: 981-6.
55. Sheehan P, Blennerhassett J, Vasikaran SD. Decision limit for troponin 1 and assay performance. Ann Clin Biochem 2002; 39: 231-6.
56. Koukkunen H, Penttilä K, Kemppainen A et al. Differences in the diagnosis of myocardial infarction by troponin T compared with clinical and epidemiologic criteria. Am J Cardiol 2001; 88: 727-31.
57. Kontos MC, Fritz LM, Anderson FP et al. Impact of the troponin standard on the prevalence of acute myocardial infarction. Am Heart J 2003; 146: 446-52.
58. Ferguson JL, Beckett GJ, Stoddart M et al. Myocardial infarction redefined: the new ACC/ESC definition, based on cardiac troponin, increases the apparent incidence of infarction. Heart 2002; 88: 343-7.
59. Hamm CW. Cardiac biomarkers for rapid evaluation of chest pain. Circulation 2001; 104: 1454-6.
60. Keffer JH. The cardiac profile and proposal practice guideline for acute ischemic heart disease. Am J Clin Pathol 1997; 107: 398-409.
61. Wu AHB, Apple FS, Gibier WB et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999; 45: 1104-21.
62. McCord J, Nowak RM, McCullough PA et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin 1. Circulation 2001; 104: 1483-8.
63. O'Neil BJ, Ross MA. Cardiac markers protocols in a chest pain observation unit. Emerg Med Clin North Am 2001; 19: 67-86.
64. Christenson RH, Duh SH. Evidence based approach to practice guides and decision thresholds for cardiac markers. Scand J Clin Lab Invest 1999; 59 (suppl 230): 90-102.
65. Jesse RL. Rationale for the early clinical application of markers of ischemia in patients with suspected acute coronary syndromes. In: Cardiac Markers, 2nd ed., Wu AHB ed., Humana Press, Totowa, NJ, 2003: 245-57.
66. Morrow DA, de Lemos JA, Sabatine MS et al. The search for a biomarker of cardiac ischemia. Clin Chem 2003; 49: 537-9.
67. Delanghe J, De Buyzere M, De Scheerder I et al. Creatine determination as an early marker for the diagnosis of acute myocardial infarction. Ann Clin Biochem 1988; 25: 383-8.
68. Taes YEC, Lameire NH, De Buyzere ML et al. Exercise-induced myocardial ischemia is accompanied by increased serum creatine concentrations. Clin Chem 2003; 49: 684-6.
69. Delanghe JR, De Buyzere ML, De Scheerder IK et al. Characteristics of creatine release during acute myocardial infarction, unstable angina, and cardiac surgery. Clin Chem 1995; 41: 928-33.
70. Kurien VA, Oliver MF. A metabolic cause for arrhythmias during acute myocardial hypoxia. Lancet 1970; 295: 813-5.
71. Kleinfeld AM, Prothro D, Brown DL et al. Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol 1996; 78: 1350-4.
72. Kleinfeld AM, Kleinfeld KJ, Adams JE. Serum levels of unbound free fatty acids reveal high sensitivity for early detection of acute myocardial infarction in patient samples from the TIMI II trial. J Am Coll Cardiol 2002; 39: 312A.
73. Adams JE, Kleinfeld A, Roe M et al. Measurement of levels of unbound free fatty acid allows the early identification of patients with acute coronary syndrome. Circulation 2002; 106 (suppl II): 532.
74. Mair J, Puschendorf B, Smidt J et al. Ealy release of glycogen phosphorylase in patients with unstable angina and transient ST-T alterations. Br Heart J 1994; 72: 125-7.
75. Mair J. Glycogen phosphorylase isoenzyme BB to diagnose ischaemic myocardial damage. Clin Chim Acta 1998; 272: 79-86.
76. Rabitzsch G, Mair J, Lechleitner P et al. Immuno-enzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem 1995; 41: 966-78.
77. 2+ binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001; 268: 42-7.
78. Christenson RH, Duh SH, Sanhai WR et al. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001; 47: 464-70.
79. Bar-Or D, Winkler JV, VanBenthuysen K et al. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin 1. Am Heart J 2001; 141: 985-91.
80. Sinha MK, Gaze DC, Tippins JR et al. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003; 107: 2403-05.
81. Apple FS, Quist HE, Otto AP et al. Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clin Chem 2002; 48: 1097-100.
82. Bhagavan NV, Lai EM, Rios PA et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003; 49: 581-5.
83. Rabbani LE. Acute coronary syndromes - Beyond myocyte necrosis. N Engl J Med 2001; 345: 1057-9.
84. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
85. André P, Nannizzi-Alaimo L, Prasad SK et al. Platelet-derived CD40L. The switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-9.
86. Heeschen C, Dimmeler S, Hamm CW et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-11.
87. Varo N, de Lemos JA, Libby P et al. Soluble CD40L. Risk prediction after acute coronary syndromes. Circulation 2003; 108: 1049-52.
88. Wu AHB, Crosby P, Pagan G et al. Ischemia-modified albumin, free fatty acids, whole blood choline, B-type natriuretic peptide, glycogen phosphorylase BB, and cardiac troponin. In: Cardiac Markers, 2nd ed., Wu AHB ed., Humana Press, Totowa, NJ, 2003: 259-77.
89. Danne O, Möckel M, Lueders C et al. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 2003; 91: 1060-7.
90. Szmitko PE, Wang CH, Weisel RD et al. New markers of inflammation and endothelial cell activation. Part 1. Circulation 2003; 108: 1917-23.
91. Cipollone F, Marini M, Fazia M et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 2001; 21: 327-34.
92. de Lemos JA, Morrow DA, Sabatine MS et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003; 107: 690-5.
93. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003; 41: 37S-42S.
94. Eiserich JP, Baldus S, Brennan ML et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002; 296: 2391-4.
95. Brennan ML, Penn MS, Van Lente F et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595-604.
96. Baldus S, Heeschen C, Meinertz T et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440-5.
97. Lawrence JB, Oxvig C, Overgaard MT et al. The insulin-like growth factor (IGF)-dependent (Qp binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 1999; 96: 3149-53.
98. Bayes-Genis A, Conover CA, Overgaard MT e t al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001; 345: 1022-9.
99. Lund J, Qin QP, Ilva T et al. Circulating pregnancy-associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin 1 elevation. Circulation 2003; 108: 1924-6.
100. Qin QP, Laitinen P, Majamaa-Voltti K et al. Release patterns of pregnancy associated plasma protein A (PAPP-A) in patients with acute coronary syndromes. Scand Cardiovasc J 2002; 36: 358-61.
101. Oxvig C, Sand O, Kristensen T et al. Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. J Biol Chem 1993; 268: 12243-6.
102. Khosravi J, Diamandi A, Krishna RG et al. Pregnancy associated plasma protein-A: ultrasensitive immunoassay and determination in coronary heart disease. Clin Biochem 2002; 35: 531-8.
103. Cowie MR, Mendez GF. BNP and congestive heart failure. Progr Cardiovasc Dis 2002; 44: 293-321.
104. Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: are they merely markers of cardiac disease? Clin Chem Lab Med 2002; 40: 752-60.
105. Kay JD, Trichon BH, Kisslo K et al. Serum brain natriuretic peptide levels cannot differentiate pulmonary disease from left-heart failure if the right ventricle is dilated. Circulation 2003; 108: IV-397.
106. Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999; 31: 487-98.
107. Struthers AD. Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart 2002; 87: 97-8.
108. Cowie MR, Jourdain P, Maisel A et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003; 24: 1710-8.
109. de Lemos JA, Morrow DA. Brain natriuretic peptide measurement in acute coronary syndromes. Ready for clinical application? Circulation 2002; 106: 2868-70.
110. White HD, French JK. Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 2003; 42: 1917-20.
111. Packer MP. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure. Circulation 2003; 108: 2950-3.
112. Karmen A, Wroblewski F, LaDue JS. Transaminase activity in human blood. J Clin Invest 1955; 34: 126-33.
113. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes. Moving toward a multimarker strategy. Circulation 2003; 108: 250-2.